G-CCC

Translational Research News



This is a new edition of the **Newsletter Translational Research** with news about translational research topics, funding possibilities, G-CCC and CCC-N events and more. Our newsletters are also available on the G-CCC website.

Digital Oncology Conference 2023 – A CCC-N and Else Kröner Symposium

On March 15 and 16, 2023, the <u>Digital Oncology Conference</u> - A CCC-N and Else Kröner Symposium took place at Messe Hannover. **200 participants exchanged ideas with 25 national and international speakers** on potentials in digital oncology and cancer research. The conference was able to achieve broad visibility due to the high-quality program, high-profile speakers, and the support of well-known sponsors. Participants were able to discuss innovative topics such as computational histopathology, digital surgery, machine learning and visualization techniques to support clinical decisions and various AI and machine learning techniques to improve cancer research.

CCC-N Cancer Club

17.04.2023, 4 – 5 pm, via Zoom; Marc Schmidt-Supprian, TUM München; Balancing B Cell Responses Between Protective Immunity, Autoimmunity and Lymphomagenesis

Zoom link: https://s.gwdg.de/H1zAAc

Upcoming dates also on the **CCC-N website**:

24.04.2023, Daniel Stange, Universitätsklinikum Carl Gustav Carus, Dresden; (*Pre-)clinical organoid platform for gastric cancer*

15.05.2023, Ulrich Keller, Charité Berlin, Title tba (Hybrid, HS 552 and Zoom)

BMBF - Research collaborations on major open questions in cancer research.

Funding is provided for research consortia consisting of five to nine experimental, theoretical, and clinical research groups (for example, from the fields of clinical oncology, cancer genomics, developmental biology, evolutionary biology, biochemistry, biostatistics, bioinformatics, artificial intelligence) that are highly interdisciplinary and cooperatively organized.

The consortia are expected to pool extensive and high-level national expertise and resources within five years and show great potential to overcome challenges and obstacles to the effective prevention or treatment of cancer in the foreseeable future.

Deadline: 30.06.2023

For more information see **BMBF** website.

ICPerMed Recognition 2023

ICPerMed Recognition 2023 - fostering personalized medicine implementation through research.

The 2023 Recognition aims to honor, encourage, promote and disseminate the examples of implementation through research in Personalized Medicine.

First authors (applicants from any countries) of candidate proposals published and/or developed between January 1st, 2021 and December 31st, 2022 are eligible to apply.

Deadline: 30.04.2023; for more information see website.

canSERV: Call for Service Provision on "Advancing Personalized Oncology"

The canSERV Consortium announces its first Challenge-Call on "Advancing Personalized Oncology". Cancer Researchers in, and outside the EU are invited to apply for free access to cutting-edge transnational services with an indicative overall budget of **EUR 500,000.**

The aim of this call is to accelerate knowledge gain in personalized oncology with specific emphasis on multi-level data-based treatment guidance linked to Molecular Tumor Boards.

Deadline: 25.04.2023; for more information see website.

Save the Date – 3rd German Cancer Research Congress

The GCRC will take place at the DKFZ in Heidelberg Oct 30 - Nov 1, 2023 and will be a joint event of the DKFZ, the German Cancer Society (DKG), German Cancer Aid (DKH), the CCC-Network, the German Cancer Consortium (DKTK), and the National Centers for Tumor Diseases (NCT). For more details see GCRC website.

New Interview with CCC-N Researcher: Interview with Dr. Shiv Singh

What topics do cancer researchers work on and how exactly does innovative oncological research work? These and other questions are addressed in our interview series available on the CCC-N website.

Get insights into the work of **Dr. Singh** and his group in the Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology at the UMG. His group is interested in studying how cell-intrinsic transcriptional machineries shape the immunosuppressive tumor microenvironment in pancreatic cancer (PDAC) and how tumor-extrinsic cytokines/chemokines modulate PDAC.

Find more news also on the latest editions of the G-CCC Newsletter and the CCC-N Newsletter.

Feel free to contact us whenever you have topics to be included in this newsletter. If you do not want to receive mail from us in the future, please let us know (petra.runge-wollmann@med.uni-goettingen.de).

G-CCC Translational Research Team | Prof. Günter Schneider, Dr. Petra Runge-Wollmann & Alexander Müller